Blue Hat Interactive Q1 EPS $(0.44) Down From $0.24 YoY

Blue Hat Interactive (NASDAQ:BHAT) reported quarterly losses of $(0.44) per share. This is a 283.33 percent decrease over earnings of $0.24 per share from the same period last year.

Blue Hat Interactive (NASDAQ:BHAT) reported quarterly losses of $(0.44) per share. This is a 283.33 percent decrease over earnings of $0.24 per share from the same period last year.

Total
0
Shares
Related Posts
Read More

Aurora Touts 41% YoY Increase In International Medical Cannabis Q3 Revenue, Expands In Australia Via New Acquisition

Canadian medical cannabis company Aurora Cannabis reported its financial and operational results for Q3 2024. Net revenue increased to CAD64.4m ($42m), up from CAD61.1m in the same quarter the previous year. Medical cannabis net revenue rose by 16% to CAD45.1m, representing 70% of Aurora's consolidated net revenue. Gross profit reached CAD19.8m, up from CAD3.7m in Q3 2022, with adjusted gross profit before fair value adjustments increasing to CAD32.4m from CAD28m. The company recorded a CAD25.5m net loss compared to CAD67.2m in the same quarter in the previous year. Adjusted EBITDA came in at CAD4.3m, up from CAD3m. Miguel Martin, CEO of Aurora, said the company's international medical net revenue had seen year-on-year growth of 41%.

ACB

Read More

Halozyme Discloses That Bristol Myers Squibb Received Updated Action Date From U.S. FDA For Subcutaneous Nivolumab Co-Formulated with ENHANZE (Halozyme’s Proprietary Recombinant Human Hyaluronidase Enzyme); The Updated Goal Date Is December 29, 2024

Halozyme announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and Drug Administration for their Biologics License Application for the subcutaneous

HALO